The Children’s Tumor Foundation (CTF) Europe is delighted to announce the elevation of Sabine Moravi…
Childrens Tumor FoundationMarch 11, 2024
Our global mission
is to End NF
We are committed to fostering international collaborations
and meeting the needs of those affected by NF across the world.
2023 Top Ten
Advancements
Laying the groundwork to better the
lives of people living with NF.
NF affects 1 in every 2,000 births
NF refers to genetic disorders that cause tumors to grow on nerves throughout the body. NF includes all forms of neurofibromatosis and schwannomatosis and affects about 4 million people worldwide. Anyone can be born with NF, and it affects everyone differently. There is no cure yet.
1
FDA-approved Drug for NF, and more on the horizon
Koselugo (selumetinib) is the first FDA-approved drug for NF. CTF-funded research paved the way to this drug approval, and we are working for more approved drugs for all types of NF!
3X
the number of NF Clinical Trials in the past 10 years
There are currently 67 active clinical trials for NF – three times the number of trials than just ten years ago!
45
years of funding NF research
The Children’s Tumor Foundation was founded 45 years ago as the first grassroots organization to support patients with all types of NF.
11,000
have joined the NF Registry
The NF Registry is a secure website where people with NF can take an active role in the search for better treatments. Participating is easy and makes a difference!
20,000
patients each year visit the NF Clinic Network
The NF Clinic Network (NFCN) is the first nationwide network dedicated to improving clinical care and establishing best practices for treating individuals with NF.
CTF Knowledge Base
What are you looking for?
Search our website for news and information about NF.
Latest News
Healx to receive investment from Children’s Tumor Foundation to advance Neurofibromatosis Type 1 treatments
Milestone payments from CTF will support advance of Healx’s lead compound, HLX-1502, to clinical trials…
CTF-Funded Research Published in “Nature”
Important new study reveals that functional interactions between NF tumor suppressors drive Schwann cell tumor…
Healx to receive investment from Children’s Tumor Foundation to advance Neurofibromatosis Type 1 treatments
Milestone payments from CTF will support advance of Healx’s lead compound, HLX-1502, to clinical trials…
Young Investigator: Q&A with Clara Nogué about schwannomatosis cell lines
The Young Investigator Award (YIA) provides two-year salary support to early-career NF researchers to help…
CTF-Funded Study Utilizes Promising Blood Test for Predicting Cancer Risk in NF Patients
In a groundbreaking study funded by the Children's Tumor Foundation (CTF), researchers are developing a…
